Two recent clinical trials have been conducted using multiple peptides derived from cancer antigens, inclusive of TTK, in esophageal squamous cell carcinoma (ESCC) and non-small cell lung cancer40, 41. This evidence concerns the gene TTK and esophageal squamous cell carcinoma.